GENE ONLINE|News &
Opinion
Blog

Breast Cancer
Herceptin Hylecta bags FDA approval for HER2-Positive Breast Cancer Treatment
2019-03-04
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
Expedited Approval of Vitrakvi® Marks Many Firsts in Cancer Therapy
2018-12-04
Pfizer’s Talzenna approved for breast cancer treatment
2018-10-25
Roche’s breast cancer drug, Kadcyla succeeds phase III trial
2018-10-22
CFDA processes priority review of BGI’s BRCA1/2 gene testing kit
2018-07-11
PARP inhibitors in cancer – BRCA or no BRCA
2018-07-03
1 2 3 4
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!